TAK-279 Dose 2 for Crohn's Disease

"Eligible participants for this research study must be over 18 years old but under the age of 75."

"Yes, information available on clinicaltrials.gov confirms that this investigation is currently seeking eligible participants. The trial was initially shared on the platform on March 5th, 2024, with the most recent update dated April 2nd, 2024. Recruitment aims to enroll a total of 268 individuals across ten designated sites."

"Indeed, the current information on clinicaltrials.gov confirms that patient recruitment is ongoing for this investigation. The study was first listed on March 5th, 2024 and last updated on April 2nd of the same year. A total of 268 participants are sought from ten different sites."

"This medical trial is enrolling 268 individuals aged between 18 and 75 who are presently managing Crohn's disease. Eligible participants must adhere to the subsequent requirements: Male or female within the age range of 18-75 years with a confirmed diagnosis of CD for a minimum duration of 30 days., The presence of moderately to severely active CD as determined by SES-CD and CDAI is mandatory., Individuals should have experienced an insufficient response, loss of efficacy, or intolerance to at least one standard or biological treatment for CD., Compliance with contraception guidelines is also imperative."

"Patients are currently being enrolled at United Medical Doctors in Murrieta, California; GI PROS, Inc. in Naples, Florida; and West Central Gastroenterology, LLP (Gastro Florida) in Clearwater, New york. Additionally, recruitment is ongoing at 10 other undisclosed sites."

"The safety assessment for TAK-279 Dose 2 is rated at 2 by our team, based on the Phase 2 trial status. This indicates existing data supporting safety but lacking evidence of efficacy."